Ionis Pharmaceuticals Receives Price Target Increase from Oppenheimer Amid Positive Growth Outlook Oppenheimer raised Ionis Pharmaceuticals’ (NASDAQ:IONS) price target from $65.00 to $72.00, while affirming its Outperform rating on the stock. This decision...
Chubb Limited (NYSE: CB), a prominent player in the insurance industry globally, has revealed plans through its subsidiary, Chubb INA Holdings Inc., to issue senior notes worth $1 billion with a 5.000% interest rate, set to mature in 2034. These notes, backed by Chubb...
Arkhouse Management, a real estate-focused investment firm, announced on Sunday that it, alongside Brigade Capital Management, has increased its bid for Macy’s following the retailer’s dismissal of their initial offer as inadequate. The revised proposal...
Kinetik (NYSE: KNTK), a prominent figure in the energy sector, has concluded a prosperous financial year marked by a remarkable achievement in adjusted EBITDA, soaring to $839 million, coupled with a record-breaking surge in processed gas volumes. Eyeing the horizon,...
Viking Therapeutics, Inc. (NASDAQ: VKTX), a biopharmaceutical leader in metabolic and endocrine disorder treatments, has set the stage for a significant financial stride. They’ve priced an underwritten public offering of 6,471,000 shares of common stock at...
During the Q4 2023 earnings call, Aaron’s Inc. (NYSE: AAN) unveiled a nuanced financial narrative marked by substantial e-commerce advancements and cost-saving initiatives, tempered by hurdles in its BrandsMart division and a scaled-back lease portfolio....
